From Breakthrough
to Bedside
DimiCare’s technology is the result of a clear Market-driven strategy and a deep research integration between the Chemistry Institute of Nice (ICN UMR7272 CNRS) and the Mediterranean Center for Molecular Medicine Research (U1065 INSERM).
We bridge the gap between high-level public research and the market, translating scientific excellence into transformative biopharmaceutical solutions to outsmart resistance development.
DCB001 - a new class of antibiotics against Skin infection
Every year, over 500 million people suffer from bacterial skin infections. As multidrug resistance rises, the medical community is shifting away from antibiotics to preserve their efficacy only to fall into a new trap. The widespread use of antiseptics is now driving cross-resistance, creating "super-pathogens" that evade both chemical and medicinal treatments...
Improperly treated, these infections escalate from routine to life-threatening. The only sustainable path forward is a new generation of antibacterials: a strategy capable of eliminating the pathogen without damaging the protective host microbiota or promoting further resistance...
DimiCare develops DCB001 within this One Health-focused and sustenable vision.
100%
Multidrug-resistant strains tested are eliminated
We have validated our technology against tens of human and veterinary clinical isolates.
Our lead compound demonstrated consistent, clear efficacy across every strain tested, proving its potential as a robust solution for both human medicine and animal health.
x5
Less resistance development compared to current antibiotics
While current ABSSSI standards of care often trigger bacterial resistance within just 2 to 5 days in in vitro models, DCB001 has demonstrated a transformative resistance profile. In comparative studies against gold-standard antibiotics, no resistance development was observed even after 30 days of continuous treatment.
This represents a major leap forward in sustainable antimicrobial therapy
1%
Efficace dose 50 for DCB001
Our lead compound has demonstrated clear preclinical efficacy, achieving non-inferiority against the current clinical standard-of-care at comparable concentrations.
This confirms DimiCare’s potential to compete directly with leading therapies in the treatment of acute bacterial skin and skin structure infections.